Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-982470 · 1 trial · 1 indication
Based on the dose-limiting toxicity (DLT) rate
Based on medical review of AE reports and the results of vital sign measurements, physical examinations, medical history, and clinical laboratory tests
| Arm | Type | Description |
|---|---|---|
| Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab | EXPERIMENTAL | Dose Escalation |
| Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab | EXPERIMENTAL | Dose Escalation |
| Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab | EXPERIMENTAL | Cohort Expansion |
| Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab | EXPERIMENTAL | Cohort Expansion |
| Part 2 - Arm 3: Ipilimumab monotherapy | ACTIVE_COMPARATOR | Cohort Expansion |
| Name | Type | Description |
|---|---|---|
| BMS-982470 (recombinant interleukin-21) | BIOLOGICAL | Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response |
| Ipilimumab | BIOLOGICAL | Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Unresectable Stage III or Stage IV melanoma * Part 1 Dose Escalation: Prior melanoma treatment allowed except for the following: ipilimumab, BMS-982470 (rIL-21), anti-Progra...
Top 20 of 51 competitors
BMS-982470 is an investigational monoclonal antibody being developed for the treatment of melanoma, a type of skin cancer. It is currently in Phase 1 clinical development, meaning it is being studied for safety and dosing in humans. As an investigational drug, it has not yet been approved by regulatory authorities.
BMS-982470 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company. Bristol-Myers Squibb is publicly traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy for melanoma.
BMS-982470 is in Phase 1 clinical development. This early-stage trial is designed to evaluate the safety, tolerability, and pharmacokinetics of the drug in patients with melanoma. The Phase 1 study has been completed, and the drug remains investigational, meaning it is not yet approved for commercial use.
BMS-982470 has been studied in one clinical trial, identified as NCT01489059. This Phase 1 study, titled "Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma," enrolled 42 participants with melanoma. The trial was conducted in the United States and Puerto Rico and has been completed.
BMS-982470 is a monoclonal antibody, a type of targeted therapy designed to bind to specific proteins involved in disease. In the context of melanoma, it is being studied in combination with ipilimumab, another monoclonal antibody. The exact molecular target of BMS-982470 has not been disclosed in available information.